Crispr/cas system and uses thereof
AssigneeHuiGene Therapeutics Co., Ltd.
InventorXing Wang
Life of this patent
Estimating the term…
Abstract
The invention provides novel CRISPR/Cas compositions and uses thereof for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13c, Cas13d, Cas13e, or Cas 13f effector protein, and at least one targeting nucleic acid component such as a guide RNA (gRNA) or crRNA. The novel Cas effector proteins are among the smallest of the known Cas effector proteins, at about 800-900 amino acids in size, and are thus uniquely suitable for delivery using vectors of small capacity, such as an AAV vector.
Claims66
A Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas complex, comprising:
- (1) an RNA guide sequence comprising a spacer sequence capable of hybridizing to a target RNA, and a direct repeat (DR) sequence 5′ or 3′ to the spacer sequence;
- and,
- (2) a CRISPR-associated protein (Cas) having an amino acid sequence of any one of SEQ ID NOs:
- 2-7 and 9-17, or a derivative or functional fragment of said Cas;
- wherein the Cas, the derivative, and the functional fragment of said Cas, are capable of (i) binding to the RNA guide sequence and (ii) targeting the target RNA, with the proviso that the spacer sequence is not 100% complementary to a naturally-occurring bacterialphage nucleic acid when the complex comprises the Cas of any one of SEQ ID NOs:
- 2-7 and 9-17.
A polynucleotide encoding any one of SEQ ID NOs:
- 2-7 and 9-17, or a derivative thereof, or a functional fragment thereof, or a fusion protein thereof, or a polynucleotide at least about 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical thereto, provided that the polynucleotide is not any one of SEQ ID NOs:
- 1 and 8.
A non-naturally occurring polynucleotide comprising a derivative of any one of SEQ ID NOs:
- 19-24 and 26-34, wherein said derivative (i) has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) nucleotides additions, deletions, or substitutions compared to any one of SEQ ID NOs:
- 19-24 and 26-34;
- (ii) has at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 97% sequence identity to any one of SEQ ID NOs:
- 19-24 and 26-34;
- (iii) hybridize under stringent conditions with any one of SEQ ID NOs:
- 19-24 and 26-34 or any of (i) and (ii);
- or (iv) is a complement of any of (i)-(iii), provided that the derivative is not any one of SEQ ID NOs:
- 19-24 and 26-34, and that the derivative encodes an RNA (or is an RNA) that has maintained substantially the same secondary structure as any of the RNA encoded by SEQ ID NOs:
- 19-24 and 26-34.
A eukaryotic cell comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas complex, said CRISPR-Cas complex comprising:
- (1) an RNA guide sequence comprising a spacer sequence capable of hybridizing to a target RNA, and a direct repeat (DR) sequence 3′ to the spacer sequence;
- and,
- (2) a CRISPR-associated protein (Cas) having an amino acid sequence of any one of SEQ ID NOs:
- 2-7 and 9-17, or a derivative or functional fragment of said Cas;
- wherein the Cas, the derivative, and the functional fragment of said Cas, are capable of (i) binding to the RNA guide sequence and (ii) targeting the target RNA.
Dependencies are inferred from the claim text.